Major breakthroughs in the product technology of these 11 pharmaceutical companies

Medicine Network January 23rd , technology changes the world, innovation determines the futureOn January 9th, the National Science and Technology Awards Conference was held in Beijing, and there were a few award-winning projects in which domestic well-known pharmaceutical companies were includedIn the field of chemical medicine technology, Shenzhen Osa Pharmaceuticals, Yuekang Pharmaceuticals, Shandong Luoxin, Beijing Jialin, Jiangsu Hengrui and other 11 enterprises won the national scientific and technological progress award second prizeSo what technologies do these companies have won? How have their sales performance been in the past?a class of new drugs, an additional 21% reductionthe risk of new stroke
Shenzhen Osa Pharmaceuticals developed a new class of new drugs, Inapriyl acid tablets (ie), and supporting MTHFRC677T gene diagnostic kit composed of stroke precision prevention productpairs, is the "China stroke precision prevention strategy conversion application" project core contentAs a cardiovascular system drug, inapriary acid reduces the risk of new stroke by an additional 21% compared to other antihypertensive drugs, and also has a good effect on the protection of kidney functionYiye listed in 2008, according to the Minet China's urban public hospitals, county-level public hospitals, urban communities, township hospitals four chemical drug market terminal competition pattern data show that Shenzhen Osa Pharmaceutical's market share before 2015 accounted for 100%, 2015 market share of 99.78%;crystal key technology four representative drugs, sales of more than 10 billionThe establishment and application of the key technology system of chemical drug crystal type, in view of the key technical problems of crystal type which restrict the development of chemical drugs in China, has realized the historic leap of crystal drug technology from scratch to match the international advanced technology level after 17 years of researchMainly by Yuekang Pharmaceuticals, Shandong Luoxin Pharmaceuticals, Tianjin Pharmaceutical Research Institute, Beijing Jialin Pharmaceuticals, Shandong Yikang Pharmaceuticals jointly invested in research and developmentYuekang Pharmaceuticals, in response to the urgent need to restrict the research and industrialization of cephalosporine drug crystal in China, set up a cephalosporine drug crystal research laboratory to carry out crystal-type research and crystal-shaped improvement of large productsThe company's product, Omeprazole, is the core application of the projectShandong Luoxin Pharmaceuticals has made important contributions to technology implementation, variety selection and crystal industrialization by conducting research in crystal innovation and imitation drug research and development and industrializationLansolaandand and cephalosporine series of crystal products from crystal raw materials to preparation research and production, the establishment of crystal product crystallization systemTianjin Pharmaceutical Research Institute began to work on the innovation of drug improvement many years ago"Adefoveester (Dedine)" is a patent limitation from the crystal type, is a representative case of the key technology application of chemical drug crystal typeBeijing Jialin Pharmaceuticals focuses on cardiovascular drugs and anti-tumor drugsSupported by crystal-based drug technology and supported by experimental data applied by this technology, and with the application of drug crystal-type technology, a full crystal-shaped research was carried out on the raw material atovastatine calcium, the main product of Jialin PharmaceuticalsAccording to the four major chemical drug terminal competition patterns of China's urban public hospitals, county-level public hospitals, urban communities and township hospitals, the total sales of the above four drugs exceeded 10 billion yuan in 2013-2015, of which the annual sales of Lansolain in Luoxin, Shandong Province, and Attovastin in Jialin, Beijing, were more than 1 billion yuanomeprazole, which is an anti-acid and anti-ulcer drug, and The sales of Omeprazole of Yuekang Pharmaceutical Group increased year-on-year in 2013-2015, with year-on-year growth from 16.83 percent to 28.14 percent, with sales exceeding 300 million in 2015Adfoveester, an anti-infective drug used throughout the bodyAccording to the data in the competitive landscape of china's urban public hospitals, urban communities, county-level public hospitals and township hospitals, its sales in 2015 reached 220 million yuan, accounting for 11.47 percent of the marketattavastatin is a blood lipid-lowering drug, in 2015 China's urban public hospitals, county-level public hospitals, urban communities, township hospitals four Chinese medicine pattern cerebrovasculardiseasedrug market TOP20 products (the first is foreign company Big Brother Pfizer), in 2013-2015 accounted for a quarter of the market sharebreak through technical barriers, The restoration of the of the trisvastattin calcium preparation process"the construction and clinical rational application of the new preparation system for the industrialization of shvastatin calcium and preparations" by Lunan Bate Pharmaceutical Co., Ltd., Nanchang University, Shandong New Era Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Co., Ltdjointly invested in researchthis project breaks through the foreign patent technology barrier, studies the new process of ruischvastatin preparation, comprehensively systematically studies the impurity spectrum attribution and photomorphic mechanism, thus achieving the goal of significantly reducing the impurity content, and for the first time systematically studies the clinical pharmacokinetic characteristics and racial differences of the new crystal of Reschvastatin in the Chinese group, and proposes that 5 mg is suitable for the Chinese group of the dose of the drug and OATP1B1 point 521Ttresupvastattin is the most internationally recognized and powerful liposuction drug, can reduce ldl lipoprotein up to 46%, increase HDL 7.7%, mainly used in the clinical treatment of high-lipid patients, but also for high risk of heart disease but blood lipids are not high healthy people, fda approved as a treatment and prevention drug  according to the , according to the data of Internet, Lunanbet Pharmaceutical's Ruishuvasttatin in China's urban public hospitals, urban communities, county-level public hospitals, township hospitals in the four major chemical drug terminal competition pattern, 2013-2015 sales increased year by year, 2015 sales exceeded the 450 million yuan mark The market share also increased from 9.40% in 2013 to 12.85% in 2015 from imitation to creation, easy to synthesize oral anti-tumor drugs is expected to come out
"complex structure natural products anti-tumor drug research and development and its industrialization" project broke through the constraints of complex structure natural products anti-tumor drugs Ilitikang and Changchun Ruibin industrialization technology bottleneck, at the same time, broke through the complex structure of natural products fujino-yellow acid drug-effect skeleton of the chemical synthesis of key technologies, through skeleton reconstruction found easy synthesis, oral candidate drugs and pre-clinical research the main participants in the project - Jiangsu Hengrui Pharmaceutical Co., Ltd., is a large-scale pharmaceutical marketed enterprises, including scientific research, production and sales, is the , is the largest anti-tumor drug research and production base, anti-tumor drug sales in the country ranked first  according to the , Jiangsu Hengrui Pharmaceuticals in China's urban public hospitals , urban communities, county-level public hospitals, township hospitals, township hospitals in the four major chemical drug terminal competition pattern, the total sales in 2015 13.547 billion yuan, an increase of 20.62 percent year-on-year Among them, anti-tumor drugs for 5.3 billion yuan, accounting for 39.33%, is the company's strong field With the company's strong research and development capabilities and sales capabilities, I believe that Hengrui's anti-tumor drugs market share will be further improved National Science and Technology Progress Award is the most authoritative and influential award in the field of science and technology, representing the highest honor of scientific and technological progress Enterprises in the thousands of military and horse outstanding to win the award, reflecting its considerable technological innovation and research and development strength, which also continue to promote enterprises in the field of research unremitting efforts, adhere to enterprise innovation, accelerate the process of internationalization of technology Let's look forward to 2017 more enterprises selected for the National Science and Technology Award, and create brilliant